Delivery Order SPE2DR25D3103-SPE2DR26F0B4N
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Aprepitant 80 mg capsule unit dose packages in quantities of six, with a contract ceiling value of $10,700.65. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and the order is scheduled for completion...
- The Defense Logistics Agency awarded a delivery order valued at $12,127.84 to AmerisourceBergen Drug Corp for Aprepitant 125 mg capsule unit dose packages (6 count) on February 3, 2026, with completion scheduled for February 4, 2026. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $4,373.58 to AmerisourceBergen Drug Corp for the supply of Aprepitant 40 mg capsules in unit dose packaging. This is a firm fixed-price, competitively awarded contract with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania facility, with an ultimate completion date of February 4, 2026. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. (doing business as AmerisourceBergen), is a major...
- The Defense Logistics Agency awarded a $1,792.44 delivery order to AmerisourceBergen Drug Corp for the supply of Aprepitant 80 mg capsules (6-count units) under a firm fixed price contract. This non-set-aside award was issued on December 12, 2025, with an ultimate completion date of December 15, 2025. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,756.25 to AmerisourceBergen Drug Corp for the supply of Aprepitant 40 mg capsules in unit dose packaging. This competitively awarded, firm fixed-price order, which originated under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999.999 billion through December 2026), will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a delivery order valued at $2,505.27 to AmerisourceBergen Drug Corp for Aprepitant 40 mg capsule unit dose packages (5 count). The contract, executed on December 17, 2025, with an ultimate completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in...
- The Defense Logistics Agency awarded a delivery order valued at $1,459.88 to AmerisourceBergen Drug Corp for Aprepitant 40 mg capsule unit dose packages (quantity 5) on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed price delivery order issued under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $11,086.37 to AmerisourceBergen Drug Corp for the supply of Aprepitant 80 mg capsules in unit dose packaging (six-count). This order was competitively awarded without set-aside designation and carries a firm fixed price contract type, with an ultimate completion date of November 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Aprepitant 40 mg capsule unit dose 5-count packages, valued at $10,666.78 with a firm fixed price structure. The contract, awarded on December 23, 2025, with an ultimate completion date of December 24, 2025, represents a non-competitive set-aside delivery order executed through AmerisourceBergen's existing indefinite delivery contract vehicle. The point of performance is located in...
- The Defense Logistics Agency awarded a $14,720.65 delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Aprepitant 40 mg capsules in unit dose packages of five (5s). This is a firm fixed price delivery order with a completion date of December 5, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's capability to meet federal...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F0B4NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $35,787.92 to AmerisourceBergen Drug Corp for the supply of Aprepitant 80 mg capsules in unit dose packages of six. The award, issued on February 4, 2026, carries an ultimate completion date of February 5, 2026, and employs firm fixed-price pricing with no set-aside designation. The contract was competitively awarded to AmerisourceBergen's corporate office, which maintains its place of performance in Conshohocken, Pennsylvania. This delivery order represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 million through December 2031. AmerisourceBergen serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, supplying an extensive portfolio of prescription medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Aprepitant, an antiemetic medication commonly used to prevent nausea and vomiting associated with chemotherapy and post-operative settings, aligns with the company's role in delivering specialized pharmaceutical commodities to support the Defense Health Agency and other government healthcare institutions. The competitive nature of this award and the firm fixed-price structure demonstrate the company's established capability to meet federal procurement requirements for essential medical supplies within the military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.8k | 2/3/26 |